As a Wall Street biotechnology entrepreneur, Dr. Rosenwald is also a member of the Orion Biomedical Fund, LP and Orion Biomedical Offshore Fund, LP. These investment companies  both participate in financing start-up pharmaceutical research labs. Dr. Lindsay Rosenwald and his team seek out cutting edge bio-pharma companies and provide the needed capital for their research to move forward and he is responsible for the founding and re-capitalization of dozens of public and private companies.

Dr. Lindsay Rosenwald and the Paramount Capital portfolio of companies have found success with three new chemical entities recently approved by the Food and Drug Administration (FDA). They currently have dozens of other compounds in the clinical trial stage. One of the portfolio companies, PolaRx BioPharmaceuticals, Inc., has recently received final marketing approval for its leukemia drug called arsenic trioxide. The approval came quickly, only 30 months after the initial patient was treated in a corporate clinical trial.

One of his more successful acquisitions, Cougar Biotechnology, developed an exciting drug for late stage prostate cancer called abiraterone acetate. Dr. Lindsay Rosenwald has financed or founded a long list of other cutting edge companies such as Genta, Inc, Repligen Corporation, Cypress Bioscience, Inc., Discovery Laboratories, Inc., and Avigen, Inc.

Dr. Rosenwald graduated from Pennsylvania State University majoring in Finance and Economy graduating Beta Gamma Sigma in 1977. From 1977 to 1979, Dr. Rosenwald worked as an independent management consultant for several health care businesses. Later, he entered Temple University School of Medicine and graduated in 1983. Next Dr. Rosenwald took an internship at Abington Medical Hospital, working in a private medical practice until 1986. At this time, he took a position on Wall Street serving as a financial analyst specializing in medical research investment opportunities.

Today, Dr. Lindsay Rosenwald is well known in both the world of investing and the medical research field. He is a visionary with an eye toward innovation in drug research and development. He has over 20 years of experience in these areas and focuses on creating and promoting pioneering medical technologies that will enhance and transform the horizons of today’s life sciences and biotechnology companies.

Mr. Michael S. Weiss in conjunction with Dr. Lindsay Rosenwald founded the OpusPoint Partners in 2009 and has steadfastly reaped success after success performing above the goals which would have been predicted. In less than two years, they’ve helped in the financing of over twenty companies, applying basic principles to best practices and processes. This has produced excellent rewards in both worlds of drug researching and business financing.

OpusPoint Partners has a promising future under the guidance of these two men who are both passionate about the world of biotechnology and have jointly founded other biotech companies through the years. With a combined 40 year track record between them in the fields of biotech and life sciences investing, there is no doubt that their experience and expertise would be instrumental in changing the way that the diagnosis and subsequent medical treatment of patients is handled.

Biotech investing is expected to be taken to a new level and OpusPoint Partners and Dr. Lindsay Rosenwald have raised the standards for advising and investing in biotechnical facilities by insisting on a strong set of values which are then reinforced by strong business principles. Investors are then provided with optimal returns with minimized risk, a formula which has already been proven effective by their successes.

Overcoming age-old techniques and procedures in medicine and healthcare will require additional effort but Dr. Rosenwald believes that this can be achieved while remaining within ethical boundaries as long as there is an injection of time, money and dedication.

The temptation to ignore ethics in exchange for greater profits has to be resisted if the founding principle of OpusPoint Partners is to be maintained. This principle is built on strong business connections with both the biotechnology and investment communities, thereby establishing a strong and successful conglomeration of partners that remain committed to honesty and integrity within the world of life science and healthcare.

The key to continued achievements in this area is the practice of integrity which has been stamped by honest investing and full open disclosure. True strength comes when companies and industry leaders have established strong relationships sharing the same values that understand that integrity is an inbuilt part of every organization’s culture and not just a good business practice. The world has become more competitive and business leaders are facing temptations of using less than ethical tactics in order to provide positive outcomes from their clinical trials to force an improvement in their earnings and profits.

OpusPoint Partners has proven that it is firmly committed to its shareholders made up of investors and employees and being different by remaining fair in all of its dealings especially when it comes to the investigating, testing and manufacture of drugs.

Dr. Lindsay Rosenwald is no stranger to merging biotechnology with financial investing. On July 10, 2009, Johnson and Johnson acquired a company called Cougar Biotech Labs for approximately one billion dollars which Dr. Rosenwald had founded under the name Cougar Biotechnology Inc. This Los Angeles based company performs research on experimental cancer drugs and has captured the interest of researchers and investors with some impressive experimental drugs that show promise. The company has already achieved success with one of these drugs which has shown great results in the treatment of latter staged prostate cancer.

Dr. Rosenwald has more than 17 years of experience as a biotechnology entrepreneur on Wall Street he has actively founded and recapitalized both private and public companies that are focused on biotechnology and life sciences. His B. S. in Finance from Pennsylvania State University and M. D. from the Temple University School of Medicine was very useful in his management of the Aries Funds (1994 to 2000) and the Orion Fund (2002-2006). The Aries fund has applied more than $1 Billion on healthcare investments while the Orion Fund has dedicated itself to private biotechnology investing in projects like PIPEs.

Dr. Lindsay Rosenwald has formed close connections to the biotechnology-finance industry leaders and is currently a member of the Board of Directors at the Republican Jewish coalition. OpusPoint Partners has geared up to prepare for the advances in healthcare and life science. Additional time and money will be invested in order to be the leaders in the latest innovations that are expected to revolutionize how healthcare is delivered. Their vision is to see a world improved by their collective input into healthcare and medicine, knowing that the future of mankind is stronger and healthier.

At OpusPoint Partners,we have a vision for an amazing future for the life science and healthcare industry. We believe in that vision so strongly that we are investingmoney and time to advance life sciences and biotechnology. We also believe in a strong, healthy future for human kind. With proper funding and research, we know that the quality of healthcare can be catapulted to a new and more effective level.

A Vision for the Future of Healthcare
With this vision in mind, Michael S. Weiss and Dr. LindsayRosenwald created OpusPoint Partners in 2009. These men have over 40 years of combined experience in the fields of healthcare, life sciences and biotechnology investing. Both are creative thinkers who have founded a number of biotech companies over the years.

Dr. Lindsay A. Rosenwaldhas most recently founded Cougar Biotechnology Inc.,which is a Los Angeles-based firm that focuses on the field of oncology. Cougar’s oncology portfolio includes some promising experimental drugs effective in treatingnumerousforms of cancer. One of those in particular has drawn the interests of researchers and investors. It has proven to work well at treating late-stage prostate cancer. Dr. Lindsay Rosenwald negotiated a deal with Johnson & Johnson for Cougar Biotech Labs at a price of approximately one billion dollars in July of 2009.

Achieving the Objectives
The objective of Lindsay Rosenwald and OpusPoint Partners is twofold: to move forward withintegrity in achieving long-term goals and short-termgains, and to build solid relationships in both the world of investing and biotechnology.  By establishing strong relationships withother industry leaders who share similar values, they believe that these goals and objectives can be obtained without the sacrifice of their principles and standards.

For OpusPoint Partners, honest investing with full and open disclosure is more than just good business. This is a way of life.They currently work with a wide range of corporations to create a team approach to supporting emerging new businesses in an effort to reach critical goals.  Dr. Lindsay Rosenwald and OpusPoint Partners have made a genuine commitment to discover and invest in innovative technologies in the fields of life sciences and healthcare.These pioneers of research and investment believe in a better future for us all; a future where diseases are diagnosed and treated by more effective methods.

At OpusPoint Partners, Dr. Lindsay Rosenwald, his business partners and colleagues, believe in a world where people’s lives and health are greatly improved. They believe in creating a future where mankind achieves a much stronger quality of life. Through thisunique vision they are making a true difference in theirworld. In order to attain this dream of a better tomorrow for us all, their journey often involves providing advisory services to start-up businesses.  Sometimes it requires investing in publicly-traded companies.

Raising the Bar
Dr. Lindsay Rosenwald and OpusPoint Partners, is working to raise the bar for investors. Their efforts include advising emerging biotechnical research facilities. They believe that a strong moral compass along with sound business principles can significantly minimize risks and thereby maximize returns for investors and so far, this unique formula is proving to be successful.

For the past 17 years, Dr. Rosenwald has been a well-respected Wall Street biotechnology entrepreneur. His business ethics have not gone unnoticed. He has, in fact, been instrumental in the founding and re-capitalization of dozens of private and public biotechnology and life-sciences companies. He earned his M.D. from the Temple University School of Medicine and his B.S. in Finance from Pennsylvania State University.

An Innovative Business Philosophy
During his impressive twenty-year career, Dr. Lindsay Rosenwald has founded over fifty companies and managed the Aries Funds from 1994 through 2007 with peak assets under his management in 2000 of over $1BB dedicated to healthcare investments. During the years of 2002 through 2006, he also managed the Orion Fund, which was a committed capital fund dedicated to private investments in biotechnology, in particular PIPEs.

The philosophy behind OpusPoint Partners will be to build a successful life science and healthcare network that plays fair and does not take short cuts to reach its goals. Dr. Rosenwald and his associates know that the world we currently live in often provides too many opportunities for business leaders to use less than ethical tactics to try to manipulate outcomes of clinical trials and hence increase quarterly earnings.
OpusPoint Partners is a uniqueenterprise that continually reinforces its commitment to its employees and investors. Their promise is to deal fairly in all aspects of experimental drug trials. In the investigation and manufacture of experimental drugs, they are resolute about these vows.

The Benefits of Making the World a Better Place
The future of OpusPoint Partners remains highly promising with Michael S. Weiss and Dr. Lindsay Rosenwald as its founders. They are utilizing their expertise in the fields of medicine and investments to effect some very real changes in the way diseases are diagnosed. They believe that the treatment of patients can be transformed.
But revolutionizing these age-old medicaland healthcare techniques and procedures is no small task, nor is it for the faint of heart. In order to effect changes on such a grand scale requires commitment; it requires time and money.  It also involves a strong resolve to work hard within the ethical boundaries that other drug research companies may have discarded in favor of better profits.

Dr. Rosenwaldunderscoresthe fact that over the past few years, projected goals have already been surpassed. By applying best practices and processes, OpusPoint Partners moves ahead earning superior, risk-adjusted returns and helpingto finance and support more than 20 companies in the past two years alone.  This achievement is marked by a continuing commitment to the financial world and the world of drug research.

Credentials and Lifetime Achievements
Dr. LindsayRosenwald is currently a member of the Board of Directors at the Republican Jewish Coalition. He is one of the most broadly-informed and well-connected individuals in the biotechnology finance sector.The future of OpusPoint Partners looks very promising with Dr. Rosenwald as its vanguard.

As with alllofty visionssuchas this, itwill take immense commitment from quality entrepreneurs to accomplish. Michael S. Weiss and Dr. Lindsay Rosenwald created OpusPoint Partners in 2009 with the idea of combining their 40 years of experience and business acumen working toward revolutionizing the fields of healthcare, life sciences and biotechnology investing. Both these men are well equipped to do this job and have already founded a number of biotech companies over the years.

With so much at stake, OpusPoint Partners along with Dr. Lindsay Rosenwald, is working toward making those leaps to advance and even transform the world of life sciences and biotechnology investing. Rosenwald, along with his team at OpusPoint, believe in a future where mankind significantly improves the quality of healthcare, as well as healthcare investing.

Advancements in the Future of Healthcare
Recently, Dr. Lindsay A. Rosenwaldfounded Cougar Biotechnology Inc. This Los Angeles-based company focuses on the field of oncology. Their oncology portfolio includes some very promising experimental drugs, which are proving to be effective in treatingnumerousforms of cancer.

One in particular has caused some excitement and drawn the interests of researchers and investors. It is a new drug that has been proven to work well at treating late-stage prostate cancer. In July of 2009, Dr. Lindsay Rosenwaldwas able to negotiate a deal with Johnson & Johnson for Cougar Biotech Labs at a price of approximately one billion dollars.

Realizing the Objectives
Lindsay Rosenwald and OpusPoint Partners believe they can continue to move forward with projects like these that alter healthcare significantly and produce results for the greater good of mankind. They achieve these goals with integrity, building solid relationships in both the world of investing and biotechnology.

Establishing robust relationships withother industry leaders who share similar values is a hallmark of the business strategy of both Dr. Lindsay Rosenwald and OpusPoint Partners. They believe in reaching goals and objectives through honesty, integrity and hard work. Their success has proven that you can obtain these objectives without the sacrifice ofprinciples and standards. Honest investing with full and open disclosure is more than just good business for OpusPoint Partners. This is the ideology they live by.

Creating New Partnerships for a Better Tomorrow
Dr. Lindsay Rosenwald and OpusPoint Partners currently work with a wide range of businesses and organizations to create a team approach for thesupport of emerging new businesses. They are making great strides toward building a powerful network of like-minded individuals who all possess a genuine commitment to discover and invest in innovative technologies in the fields of life sciences and healthcare.

With pioneers such as these in the areas of research and investment, you can be sure that thefuture of healthcare and life sciences will continue to flourish. These days, the medical field is well-aware of its need for diseases of all types to be diagnosed and treated by more effective methods. At OpusPoint Partners, Dr. Lindsay Rosenwald, his business partners and colleagues, know that the dream can become a reality with hard work and dedication.

The dream of a better tomorrow continues to be the fuel that fires this vision of a much stronger quality of life for us all. And thisunique vision of making a true difference in the world has become a driving force for Dr. Lindsay Rosenwald and OpusPoint Partners. History shows that dreams like this always take time, money and hard work, plus dedication from those involved.

Raising the Bar for Investors
Over the course of this journey, Dr. Lindsay Rosenwald and OpusPoint Partners must oftenprovide advisory services to start-up businesses. At times they also must invest in publicly-traded companies in order to move the vision forward.

One of their key objectives is to raise the bar for all investors. Whether working in the advisory capacity with emerging biotechnical research facilities or actually investing, OpusPoint followsa strong moral compass.With sound business principleslike these, the risks can be significantly minimizedand the returns for investors maximized. This uniqueformula has proven successful beyond anyone’s wildest dreams.

Utilizing Ethical Business Practices
The philosophy behind OpusPoint Partners is to build a positive and effective life science and healthcare network that plays fair and won’t take short cuts to reach its goals. Dr. Rosenwaldknows from experience, that today’s world often provides many opportunities for business leaders to use less than ethical tactics to try and manipulate outcomes of clinical trials with an eye toward greaterquarterly earnings. Does the end justify the means?

At OpusPoint Partners, the answer is a resounding no! This unique enterprise continually reinforces its commitment to its employees and investors to conduct business with higher standards than many of days gone by. In the investigation and manufacture of experimental drugs, they are resolute about this commitment to honest, above-board business dealings.

A Long and Fruitful Career
The future of OpusPoint Partners remains highly promising with Michael S. Weiss and Dr. Lindsay Rosenwald as its founders. They are utilizing their expertise in the fields of medicine and investments to effect some very real changes in the way diseases are diagnosed. They believe that the treatment of patients can be transformed.

Dr. Rosenwald, a well-respected Wall Street biotechnology entrepreneur, has worked for the past 17 years utilizing strong business ethics in the founding and re-capitalization of dozens of private and public biotechnology and life-sciences companies. He earned his M.D. from the Temple University School of Medicine and his B.S. in Finance from Pennsylvania State University.

Throughout an impressive twenty-year career, Dr. Lindsay Rosenwald has established over fifty companies. He also managed the Aries Funds from 1994 through 2007 with peak assets under his management in 2000 of over $1BB dedicated to healthcare investments. From 2002 to 2006, hemanaged the Orion Fund, which was a committed capital fund dedicated to private investments in biotechnology, in particular PIPEs.

Dr. Lindsay Rosenwald is currently a member of the Board of Directors at the Republican Jewish Coalition. He is one of the most broadly-informed and well-connected individuals in the biotechnology finance sector. The future ofOpusPoint Partners indeed looks promising with Dr. Rosenwald at its helm.

The research, COU-AA-002, was conducted by a national medical research group, the Prostate Cancer Clinical Trials Consortium, sponsored by the Department of Defense, with Dr. C. J. Ryan, and BioSciences, with Dr. Lindsay Rosenwald, as the leading investors.

In this trial, abiraterone acetate plus prednisone was administered to chemotherapy-naïve men diagnosed with metastatic advanced prostate cancer, whose disease progressed despite hormonal therapies. In his poster presentation, Dr. Charles J. Ryan presented data supporting the valuable effect of abiraterone on the disease decline. More than 70% of patients experienced a prostate specific antigen (PSA) decline and the median time to PSA progression wasn’t noticed even after 10 months of treatment.

Another clinical trial of abiraterone acetate was conducted at the University of Texas M.D. Anderson Cancer Center (MDACC). The patients with CRPC had all radiological evidence of metastatic prostate cancer with bone metastases. 48% of the patients experienced a decline in PSA levels and an improvement in overall performance status. All patients had also a decline in bone marrow and serum testosterone to below detectable levels.

According to Cougar Biotechnology, acquired by J&J in late 2009, abiraterone acetate continues to demonstrate potent evidence of anticancer activity in patients with advanced castrate-resistant prostate cancer. More research and investments, e.g. by Lindsay Rosenwald’s BioSciences, are needed to ensure abiraterone meets unmet medical needs in patients diagnosed with metastatic prostate cancer.

In 2010, Phase III trial, COU-AA-301, as well as COU-AA-302 trial demonstrated significant survival improvement in patients, who failed first-line hormonal or docetaxel-based treatment.

Dr. Lindsay Rosenwald is a member of Board of Directors at the Republican Jewish Coalition. His short biography can be found on their official website www.rjchq.org . Being one of the most broadly-informed and connected people in the biotechnology financing sector, Dr. Rosenwald at the head of his Capital company contributes greatly to private equity, venture capital, and hedge funds.

Dr. Lindsay Rosenwald is a notable person in the Wellness.com community. Being a general practitioner in New York, NY, and a graduate from the Temple University Medical School, Lindsay Rosenwald offers such medical care services as general physical examinations, fitness programs, cholesterol testing, bone density testing, skin biopsies, immunization, stress reduction plans, skin biopsies, menopause treatment, ongoing evaluations and more.

Lindsay Rosenwald is an honorable member of the NyICECATS, all Jewish Orthodox Youth Hockey Organization. At the 3^rd and 4^th annual Captain’s Dinner that took place in Le Marais, NYC, on March 12th, Neil Herskowitz, Director at Manhattan Pharmaceuticals, Inc., presented Lindsay Rosenwald with the gifts of team, including a new Bauers 190. In the middle of the dinner, Dr. Lindsay Rosenwald announced that he committed to another 25 years of icetime at the Piers. The dinner was finished with the grand “Golden Balls” awards ceremony.

At the Huffington Post’s FundRace 2008, the search for Lindsay Rosenwald returns his contribution to McCain Victory Committee that received the donation of $61,800 from Dr. Lindsay Rosenwald.

Among the exemplary traits of Lindsay Rosenwald and his wife is that they have set a true example for their children, not merely joining in these causes in the vicinity of their children, but actually working directly with their children in supporting many charitable causes.  These events have helped teach their children, but they have also support children’s causes through fund raisers held in their home.  Their children have learned first hand how to do good, and do it wisely.  For Lindsay Rosenwald and his family, the future of all people is a real and ever present concern.  They have repeatedly and eagerly invested in programs to help society, investing especially generously in the area of education.  Benefactors of this nature who, in addition to donations in their region have found themselves able to help specific individuals requiring financial aid, are truly hard to come by.

There is no shortage of stories about Lindsay Rosenwald’s good heart or noble actions.  One of his friends, an artist, became the beneficiary of Dr. Rosenwald’s amazing generosity.  His generosity   has been felt through the purchase of his friend’s paintings which are now proudly displayed in the Institutes lobby.  Not only generous, but humble too, Lindsay agreed to being honored at a Sh’or Yoshuv Annual Banquet with the words “I don’t like the limelight, but you know I will do what it takes to help you out.”

He was true to his word in every case.  Perhaps the most moving story to me involves a time when the Institute faced a major budget crisis.  Major deficits needed to be resolved and so a meeting was held to attend to these issues.  The meeting was held in Dr. Lindsay Rosenwald’s home.  For the vast majority of the meeting, Dr. Rosenwald was completely silent.  After long hours of listening, however, he approached the Rabi and whispered to him that he would gladly cover the entire deficit.  He did not do this publicly and did not seek to be rewarded or applauded for his offer.

Perhaps the great virtues that Lindsay Rosenwald is instilling in his children were also instilled in him by his father.  We are glad to have a building dedicated to his father, David Rosenwald, on our campus.  The Rosenwalds have been amazing friends to the Sh’or Yoshuv Institute for generations.  Their participation in High Holy Days activities and religious services has enriched those spiritual events.  Their commitment to their heritage and their community has helped to sustain a vibrant center of life within and for the Institute.  Their continued aid has helped to inspire the entire administration and has brought great hope for, and resources to create the reality of, a bright and successful future for the Institute.

When I went to be interviewed, I was led into an office.  It was there I met Lindsay Rosenwald, and we talked for nearly 6 hours.  During the interview, Lindsay handled many calls simultaneously, met briefly with a limitless parade of visitors, and placidly executed trades from his observation of four screens displaying market activity.  When the day ended, I was told I was hired.  I was to return next morning to talk over details with him.

I called my brother Tom that night to share my interview with him.  He all but yelled into the phone, “You met with who?!  Do you have any idea who Lindsay Rosenwald is?!”

It’s a vast understatement for me to say that interview changed the rest of my life.

Through Lindsay Rosenwald, I found an opportunity that very few would have presented to me.  My background was in offering basic nutritional advice, but I had no grasp of finance and public markets.  Lindsay Rosenwald took the risk though, and I was brought into the universe of venture capital, merchant banking, public corporations, and finance.  This ended up being an amazing, fast-paced, intense educational experience.  My life had changed, and I was excited.

As a valued mentor and lifelong friend, I am very thankful to Lindsay.  Lessons I learned from him that I come back to time and again:

Choose a path and remain focused on it.

Pioneers get the arrows; settlers get the land.

It’s much better to own ten percent of the mine than one hundred percent of the shaft.

Don’t concern yourself with idle gossip if it is in regards to you.  In reality it’s idol worship.

Lindsay Rosenwald is highly intelligent, works tirelessly, and is relentless.  I have great admiration for those qualities.  However, I mainly will always remember that when I was chosen to join, it was based on him seeing potentiality around him that others seem to miss.  In most regards, I had been the most longshot of candidates for the position.  Lindsay Rosenwald cultivates the potential he sees and is the architect of an environment allowing for growth, thinking, creativity, and free thought while developing technologies.

Lindsay Rosenwald has done this, started and nurtured countless successful careers, more often than can be counted.  He is rarely acknowledged and thanked for it.  Everyone he chose was talented, but though we may be hesitant to admit so, we were able to express this talent because of the selfless efforts of people like Lindsay.

Dr. Rosenwald has made incomparable contributions to the fields of biotechnology and pharmaceuticals, as reflected by the number of companies he has founded and maintained.  He is the president of the Rosenwald Foundation, a charitable foundation that supports a number of scientific and medical educational organizations. In addition, he serves as director of several pubic and private biotechnology companies and is a member of the Columbia-Presbyterian Health Sciences Advisory Counsel. He is a leading founder of successful biotechnology and pharmaceutical companies, including Biocryst Pharmaceuticals, Titan Pharmaceuticals, Cypress Biosciences, Keryx Biopharmaceuticals, Javelin Pharmaceuticals, Polarx, and Enzymed Corp.

Dr. Rosenwald continues to grow as a thriving venture capitalist and hedge fund manager. With 20 years’ experience as a pharmaceutical and biotechnology financier, he remains a leader in the world of high-tech medicine and research development.